Get the Stockscreener App
2.12
2.30%
-0.05
After Hours:
2.13
0.010
+0.47%
Coherus Biosciences Inc stock is currently priced at $2.12, with a 24-hour trading volume of 1.45M.
It has seen a -2.30% decreased in the last 24 hours and a -1.40% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.17 pivot point. If it approaches the $2.07 support level, significant changes may occur.
Previous Close:
$2.17
Open:
$2.18
24h Volume:
1.45M
Market Cap:
$243.22M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.6386
EPS:
-3.32
Net Cash Flow:
$-175.17M
1W Performance:
+11.58%
1M Performance:
-1.40%
6M Performance:
-0.47%
1Y Performance:
-57.77%
1D Range:
$2.10
$2.21
52W Range:
$1.4301
$5.63
Coherus Biosciences Inc Stock (CHRS) Company Profile
Name
Coherus Biosciences Inc
Sector
Industry
Phone
650-649-3530
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Biosciences Inc Stock (CHRS) Latest News
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Coherus BioSciences (NASDAQ:CHRS) versus Exelixis (NASDAQ:EXEL) Critical Contrast - Defense World
Defense World
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Coherus Biosciences Inc Stock (CHRS) Financials Data
Coherus Biosciences Inc (CHRS) Revenue 2024
CHRS reported a revenue (TTM) of $257.24 million for the quarter ending December 31, 2023, a +21.89% rise year-over-year.
Coherus Biosciences Inc (CHRS) Net Income 2024
CHRS net income (TTM) was -$237.89 million for the quarter ending December 31, 2023, a +18.46% increase year-over-year.
Coherus Biosciences Inc (CHRS) Cash Flow 2024
CHRS recorded a free cash flow (TTM) of -$175.17 million for the quarter ending December 31, 2023, a +27.96% increase year-over-year.
Coherus Biosciences Inc (CHRS) Earnings per Share 2024
CHRS earnings per share (TTM) was -$2.60 for the quarter ending December 31, 2023, a +30.85% growth year-over-year.
Coherus Biosciences Inc Stock (CHRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lanfear Dennis M | President & CEO |
Nov 22 '23 |
Option Exercise |
1.42 |
299,940 |
425,015 |
954,793 |
| Lanfear Dennis M | President & CEO |
Nov 22 '23 |
Sale |
2.02 |
223,100 |
449,770 |
731,693 |
About Coherus Biosciences Inc
Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
0.77%
1.20%
Cap:
|
Volume (24h):